Alkem Laboratories Limited (ALKEM)

Name: Alkem Laboratories Limited (ALKEM) — historial de estados financieros
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.

Healthcare · Wall Street (EE. UU.) · Última actualización: 2026-09-20

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally.

Cifras clave

Capitalización bursátil: ₹654 billion
Ingresos (ejercicio cerrado en 2026-03-31): ₹145.3B
Beneficio neto: ₹23.0B
Margen bruto: 64.2%
Margen neto: 15.8%

Ver gráficos interactivos y estados completos →

Cuenta de resultados anual

Cuenta de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Ingresos totales	₹145.3B	₹128.0B	₹124.4B	₹114.4B	—
Beneficio bruto	₹93.3B	₹79.5B	₹74.1B	₹64.6B	—
Ingresos operativos (EBIT)	₹26.5B	₹21.8B	₹19.8B	₹13.3B	—
Ingresos netos	₹23.0B	₹21.7B	₹18.0B	₹9.8B	—

Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.

Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de ALKEM. /companies/us/ALKEM

Empresas similares

La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.

English version →Todas las acciones

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.